Amphastar Pharmaceuticals, Inc. $AMPH Shares Acquired by LSV Asset Management

LSV Asset Management increased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 50.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 110,300 shares of the company’s stock after acquiring an additional 37,000 shares during the quarter. LSV Asset Management’s holdings in Amphastar Pharmaceuticals were worth $2,954,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. New York State Common Retirement Fund lifted its stake in shares of Amphastar Pharmaceuticals by 86.4% in the third quarter. New York State Common Retirement Fund now owns 90,169 shares of the company’s stock worth $2,403,000 after acquiring an additional 41,800 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $2,504,000. Clark Capital Management Group Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter worth about $7,560,000. SummerHaven Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter worth about $1,018,000. Finally, Denali Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 56.9% in the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock worth $5,671,000 after acquiring an additional 76,765 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the topic of several recent analyst reports. Wells Fargo & Company reiterated an “equal weight” rating and issued a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Piper Sandler reissued a “neutral” rating and issued a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Weiss Ratings lowered Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Reduce” and a consensus price target of $24.50.

Amphastar Pharmaceuticals Stock Up 2.2%

Shares of Amphastar Pharmaceuticals stock opened at $18.81 on Wednesday. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. The firm has a market cap of $829.39 million, a P/E ratio of 11.33, a P/E/G ratio of 2.98 and a beta of 0.97. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The business has a 50-day moving average price of $20.11 and a 200 day moving average price of $23.97.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). The firm had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. On average, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.93 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.